These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26392756)

  • 1. Potential drug-drug interactions in Alzheimer patients with behavioral symptoms.
    Pasqualetti G; Tognini S; Calsolaro V; Polini A; Monzani F
    Clin Interv Aging; 2015; 10():1457-66. PubMed ID: 26392756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors.
    Jones RW
    Int J Geriatr Psychiatry; 2010 Jun; 25(6):547-53. PubMed ID: 20049770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine.
    Zemek F; Drtinova L; Nepovimova E; Sepsova V; Korabecny J; Klimes J; Kuca K
    Expert Opin Drug Saf; 2014 Jun; 13(6):759-74. PubMed ID: 24845946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Alzheimer disease.
    Winslow BT; Onysko MK; Stob CM; Hazlewood KA
    Am Fam Physician; 2011 Jun; 83(12):1403-12. PubMed ID: 21671540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of Alzheimer's Disease.
    Bianchetti A; Ranieri P; Margiotta A; Trabucchi M
    Aging Clin Exp Res; 2006 Apr; 18(2):158-62. PubMed ID: 16702787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
    Blaszczyk AT; Mang BH; Garza H; Mathys M
    Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current pharmacotherapy for Alzheimer's disease.
    Lleó A; Greenberg SM; Growdon JH
    Annu Rev Med; 2006; 57():513-33. PubMed ID: 16409164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil.
    Periclou AP; Ventura D; Sherman T; Rao N; Abramowitz WT
    Ann Pharmacother; 2004 Sep; 38(9):1389-94. PubMed ID: 15266045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modern therapy for dementia].
    Padberg F; Möller HJ; Bottlender R; Hampel H
    MMW Fortschr Med; 2005 May; 147 Spec No 2():71-4, 76-7. PubMed ID: 15968877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine: pharmacological properties and clinical uses.
    Kumar S
    Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy in Alzheimer disease: an update for the oral health care provider.
    Turner LN; Balasubramaniam R; Hersh EV; Stoopler ET
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Oct; 106(4):467-76. PubMed ID: 18928896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and risks of add-on therapies for Alzheimer's disease.
    Magierski R; Sobow T
    Neurodegener Dis Manag; 2015 Oct; 5(5):445-62. PubMed ID: 26517312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors.
    Prescrire Int; 2014 Jun; 23(150):156. PubMed ID: 25121150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine in dementia: a review of the current evidence.
    Herrmann N; Li A; Lanctôt K
    Expert Opin Pharmacother; 2011 Apr; 12(5):787-800. PubMed ID: 21385152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.